Navigation Links
NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases
Date:10/2/2007

Cambridge, MA October 2, 2007 Phylonix Pharmaceuticals, Inc. today announced that it has been awarded a $1,092,031 Phase II Small Business Innovation Grant (SBIR) from the National Eye Institute of the National Institutes of Health (NIH) to develop zebrafish eye disease models for drug screening. The grant for New Models for Eye Diseases will support the Phylonix program over a period of three years.

The eye is a highly conserved organ and the basic structure between human and zebrafish eyes is indistinguishable. In addition, numerous eye diseases have been modeled in zebrafish including choroidal neovascularization, similar to age-related macular degeneration (AMD) in humans; ocular scarring that occurs after surgery for glaucoma; retinopathy induced by diabetes and edema; and ocular ischemia caused by several pathologies.

The funding for this program will be used to further develop our novel, patent pending methods for modeling eye diseases and to identify potential drug candidates, commented Patricia McGrath, Phylonix President and Chief Executive Officer. Our preliminary data show good correlation between results in zebrafish and results in mammals and we are very pleased to receive this Phase II SBIR award from the National Eye Institute.

Phylonix is modeling a number of eye diseases in zebrafish including diabetic retinopathy and AMD, the two leading causes of blindness in adults in the industrialized world. Both conditions involve vascular abnormalities, proliferation and leakage of new blood vessels. Other eye diseases resulting in blindness that Phylonix is modeling in zebrafish include retinopathy of prematurity, a major cause of newborn blindness in premature infants maintained by oxygen supplementation during the postnatal period. This disease involves intense neovascularization of the retina and leads to retinal detachment. Another cause of blindness is corneal neovascularization, which often results from injury and infection in the cornea.

Current mammalian models for ocular neovascularization require lengthy, tedious surgical manipulation and do not always result in improved vision; an alternative rapid, less invasive animal model for studying the process of ocular neovascularization and assessing drug effects will facilitate identification of new therapeutics. As the population ages, the incidence of eye diseases is rapidly increasing and convenient methods for assessing single and combination therapies in whole animals are urgently needed.

Advantages of using zebrafish for compound screening

Laboratory animals are critical for defining the mechanisms of drug activity and for testing therapeutic regimens, however, only a few useful models have been developed. Zebrafish has several important advantages for drug screening: they are small, inexpensive to maintain, and easily bred in large numbers. Zebrafish eggs are externally fertilized and a single mating produces 100-200 eggs. Single embryos can be maintained in fluid volumes as small as 100 microliters for the first six days of development and cultured in microtiter wells. Chemicals can then be added directly to the fish water, permeating the intact embryos. Standard microtiter plate readers can be used for quantitation, making this format particularly attractive for high-throughput drug screening.

Phylonix is developing a family of zebrafish assays with compelling advantages: 1) short assay time, 2) single dosing, 3) small amount of drug required for each test, 4) statistically significant numbers of animals can be assayed for each condition, 5) embryos maintenance during drug delivery is easy, and 6) low cost the estimated cost of each zebrafish assay is less than $100. Chemicals, small molecules, proteins, and nucleic acids such as knock-down reagents can be assessed using the Phylonix zebrafish assays.


'/>"/>

Contact: Edward O'Lear
ed.olear@phylonix.com
617-441-6700
Phylonix
Source:Eurekalert

Related medicine news :

1. Aussie Nobel Prize Winners Receive Their Awards
2. Prestigious Gairdner Awards for medical research in 2006 Goes To Two Yale biologists
3. The President Gives Away National Disability Awards
4. Majority of Padma Awards Go to Doctors from Delhi
5. US, Indian Doctors Bag Thai Medical Awards
6. WHO Awards Prequalification Status to the First UAE Approved Vaccine
7. Bio-Rad Gets Life Science Industry Awards – 200
8. Michael J. Fox Foundation Awards $710,000 to Understanding of Parkinsons Disease Subtypes
9. Ontario Court Awards Compensation To Paralyzed Worker
10. Talwalkars Awards a Record $1 Million Order to Nautilus
11. NIH Awards Emory $3.6 Million for Schizophrenia Gene Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... According to an article ... as a weight loss dietary supplement, is being recalled due to the discovery that ... because there is not a single supplement on the market proven to help people ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... a wide range of cosmetic procedures. Along with performing procedures, the magazine also ... results of many cosmetic procedures. One of the most common procedures he performs ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY ... System but would shift more of the cost burden to military beneficiaries. , ... out in the defense budget as including limited quantifiable benefit fixes mixed with numerous ...
(Date:2/11/2016)... ... February 11, 2016 , ... Thermi™, ... health, is pleased to announce the promotions of Allison Kelly to executive vice ... Catone to executive vice president of North American capital sales, and Wendy Oseas ...
(Date:2/11/2016)... ... 11, 2016 , ... The Commission for Case Manager Certification ... Commissioners. Individuals interested in volunteer board service are encouraged to apply. The Commission ... and across allied health to contribute to its mission and vision. The Commission ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  Walgreens has committed to provide ... and Washington, D.C. as part of ... was commended by shareholder advocacy organization As You Sow. ... Sow. "Many people hold on to unneeded drugs because they ... tragic consequences." --> Conrad MacKerron , Senior ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  NOIT™ Research ... a special "Gift of Change" campaign to assist needy ... For every such unit sold between February 10, 2016 ... unit to a needy family. The NOIT is an ... non/limited-verbal autistic individuals develop language skills. ...
Breaking Medicine Technology: